SuperworthEnanta Pharmaceuticals ENTA
- Market cap
- $339M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $65.3M
- +1% on a year ago
- Net margin
- −96.9%
- Free cash flow yield
- −10.9%
Enanta Pharmaceuticals trades at 5.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $65.3M over the last twelve months, up 1% on a year earlier with a −97% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $18.9M−7% | $18M−24% | $17.1M−4% | $18M−5% | $14.6M−23% | $17M−6% | $14.9M−13% | $18.3M+2% | $15.1M+4% | $18.6M+10% | $17.2M+15% | $14.4M−22% | |
| R&D | $36.2M+4% | $36.4M−11% | $35.6M−18% | $28.7M−33% | $30.8M−15% | $27.7M−24% | $28.1M−21% | $27.2M−5% | $23.8M−23% | $20.9M−25% | $19.4M−31% | $22.1M−19% |
| SG&A | $13.8M+10% | $16.5M+30% | $14.2M+3% | $13.4M+6% | $13.7M−1% | $12.8M−22% | $11.4M−20% | $10M−26% | $9.7M−29% | $9M−30% | $9.6M−16% | $9.5M−5% |
| −$31M+15% | −$34.9M+16% | −$32.8M−17% | −$24.2M−34% | −$29.9M−4% | −$23.5M−33% | −$24.5M−25% | −$18.9M−22% | −$18.4M−38% | −$11.3M−52% | −$11.9M−52% | −$17.2M−9% | |
| Interest expense | $3.2M | $3.4M | $2.6M | $2.4M+18% | $2.6M−18% | $2M−43% | $1.7M−33% | $1.6M−31% | $2.4M−8% | $3.1M+57% | $3.3M+94% | $4.1M+155% |
| Pre-tax income | −$29.5M+12% | −$34M+17% | −$31.5M−16% | −$23.1M−34% | −$29.2M−1% | −$22.7M−33% | −$23.9M−24% | −$18.2M−21% | −$18.7M−36% | −$11.9M−48% | −$13.1M−45% | −$19.5M+7% |
| −$1.4M | −$622K+1729% | −$363K | −$395K | −$363K−74% | −$416K−33% | −$1.3M+260% | $29K | $32K | $24K | $7K | $36K+24% | |
| Net income | −$28.1M+7% | −$33.4M+15% | −$31.2M−17% | −$22.7M−42% | −$28.8M+3% | −$22.3M−33% | −$22.6M−27% | −$18.3M−19% | −$18.7M−35% | −$11.9M−46% | −$13.1M−42% | −$19.5M+7% |
| −$1.33+5% | −$1.58+14% | −$1.47−18% | −$1.07−43% | −$1.36+2% | −$1.05−34% | −$1.06−28% | −$0.85−21% | −$0.87−36% | −$0.42−60% | −$0.45−58% | −$0.67−21% | |
| 21.1M+2% | 21.1M+1% | 21.2M+1% | 21.2M+1% | 21.2M+1% | 21.2M+1% | 21.4M+1% | 21.4M+1% | 21.4M+1% | 28.7M+35% | 29M+36% | 29.1M+36% |
Revenue: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
R&D: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
SG&A: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Operating income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY13: 6 months less the 3 months printed beside them.
Net income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
EPS, diluted: 7 periods, Q1 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY12: share-days: the 6-month average less the second quarter's. 10 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY15 to Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Enanta Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ENTAEnanta Pharmaceuticals | $339M | n/m | 25.8× | 5.2× | +1% | −96.9% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on Enanta Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .